Gray Fox Wealth Advisors LLC acquired new shares in DR Horton, Inc. (NYSE: DHI – Get Rating) in the fourth quarter, according to the company’s latest Form 13F filing with the Securities and Exchange Commission. The company acquired 939 shares of construction company stock, worth about $84,000.
Several other hedge funds have also recently changed their stock holdings. Clear Street Markets LLC purchased his new DR Horton position for his $28,000 value in the fourth quarter. Geneos Wealth Management Inc. increased its stake in DR Horton by 117.3% in the fourth quarter. Geneos Wealth Management Inc. acquired an additional 190 shares during the last quarter and now owns 352 shares of the construction company, valued at $31,000. Concord Wealth Partners purchased a new position in DR Horton in the fourth quarter for a value of approximately $32,000. Fairfield Bush & Colorado bought a new position in his DR Horton stock worth about $28,000 in the first quarter. Finally, Creative Capital Management Investments LLC purchased a new position in DR Horton stock worth approximately $36,000 in the fourth quarter. Hedge funds and other institutional investors own 84.87% of the company’s shares.
Wall Street analyst speaks out
A number of equity research analysts have recently voiced their opinions on the company. In a research report on Monday, March 6, JPMorgan Chase lowered its rating on DR Horton to “neutral” from “overweight” and lowered its price target to $102.50 from $107.00. Barclays raised its price target on DR Horton to $138.00 from $131.00 in a research note on Wednesday, May 24. Keefe, Bruyette & Woods reiterated its “market perform” rating for DR Horton stock in a research note on Tuesday, April 25. UBS Group raised its price target on DR Horton from $122.00 to $134.00 in its report on Friday, April 21, giving the stock a Buy rating. Finally, Citigroup raised its price target on DR Horton to $124.00 from $115.00 in its Friday April 21 report. One research analyst issued a sell rating, eight hold ratings, and nine buy ratings on the company’s stock. The company has a consensus rating of Hold and an average price target of $112.72, based on MarketBeat data.
In related news, COO Paul J. Romanowski sold 40,000 shares in a trade on Wednesday, May 17th. The shares were sold at an average price of $112.16 for a total transaction value of $4,486,400.00. Following the closing of the transaction, the Chief Operating Officer will directly own 84,268 shares of the Company’s stock valued at $9,451,498.88. The transaction was disclosed in filings with the Securities and Exchange Commission, which are available on the SEC’s website. In other news from DR Horton, his COO Paul J. Romanowski sold 40,000 shares of the company in his Wednesday, May 17th deal. The shares were sold at an average price of $112.16 for a total transaction value of $4,486,400.00. Following this transaction, the Chief Operating Officer now directly owns 84,268 shares of the company, valued at $9,451,498.88. The sale was disclosed in documents filed with the Securities and Exchange Commission, available at this link. In addition, director Barbara K. Allen sold 449 shares of the company in a transaction on Monday, March 13. The stock sold at an average price of $96.00, giving him a trading value of $43,104.00. Following the transaction, the directors now own 5,650 shares of the company’s stock valued at $542,400. Disclosure information regarding this sale can be found here. Insiders have sold 94,652 shares worth $10,500,466 in the past 90 days. Corporate insiders own 0.61% of the company’s stock.
DR Horton deal up 0.7%
The NYSE DHI opened Friday at $114.01. The stock has a market cap of $38.89 billion, trades for 7.69 times earnings, 0.66 times earnings, and 1.53 times beta. DR Horton hit a 52-week low of $59.25 and a 52-week high of $116.26. Its 50-day moving average price is $106.40 and its 200-day moving average price is $97.53. The company has a quick ratio of 1.27, a current ratio of 6.80 and a debt to equity ratio of 0.28.
DR Horton (NYSE:DHI – rated) last reported quarterly results on Thursday, April 20th. The construction company reported earnings per share (EPS) of $2.73 for the quarter, $0.83 above consensus expectations of $1.90. The company’s revenue for the quarter was $7.97 billion, compared with analysts’ expectations of $6.48 billion. DR Horton’s net margin was 15.39% and his return on equity was 25.94%. The company’s revenue for the quarter fell 0.3% year-on-year. In the same period last year, the company posted earnings of $4.03 per share. Equity research analysts expect DR Horton, Inc.’s EPS to be his $11.19 for the current year.
DR Horton Announces Dividend
The company also recently announced a quarterly dividend, which was paid out on Wednesday, May 10. His dividend of $0.25 per share was issued to investors of record on Wednesday, May 3. The ex-dividend date for this dividend was Tuesday, May 2nd. This equates to an annualized dividend of $1.00 and a yield of 0.88%. DR Horton’s payout ratio is currently 6.74%.
About DR Houghton
DR Horton, Inc. is a residential construction company that builds and sells single-family homes. It operates through the Northwest, Southwest, South Central, Southeast, East and North geographic segments. The Northwest segment includes Colorado, Oregon, Utah, and Washington.
Want to know if other hedge funds hold DHI? Visit HoldingsChannel.com to get DR Horton, Inc.’s (NYSE: DHI – Get Rating) latest 13F filings and insider trading.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments regarding this story to email@example.com.
Listen to this before you consider DR Horton.
MarketBeat tracks Wall Street’s highest-rated, highest-performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are secretly whispering to customers to buy now before the whole market goes up…and DR Horton wasn’t on that list.
DR Horton is currently rated “Hold” among analysts, but high-scoring analysts think these five stocks are better buys.
Click here for 5 brands
20 stocks you can sell right now
MarketBeat has released a list of 20 stocks selected by Wall Street analysts. dislike. While these companies may appear to have good fundamentals, top analysts smell something seriously rotten.Are these companies lurking around your portfolio? Please enter your email address below and confirm.
Get This Free Report